CA2581834A1 - Novel crystal form of (3-cyano-1h-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone, hydrochloride - Google Patents
Novel crystal form of (3-cyano-1h-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone, hydrochloride Download PDFInfo
- Publication number
- CA2581834A1 CA2581834A1 CA002581834A CA2581834A CA2581834A1 CA 2581834 A1 CA2581834 A1 CA 2581834A1 CA 002581834 A CA002581834 A CA 002581834A CA 2581834 A CA2581834 A CA 2581834A CA 2581834 A1 CA2581834 A1 CA 2581834A1
- Authority
- CA
- Canada
- Prior art keywords
- crystal form
- indol
- cyano
- methanone
- piperazin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000013078 crystal Substances 0.000 title claims description 38
- AQRLDDAFYYAIJP-UHFFFAOYSA-N Pruvanserin Chemical compound C1=CC(F)=CC=C1CCN1CCN(C(=O)C=2C=3NC=C(C=3C=CC=2)C#N)CC1 AQRLDDAFYYAIJP-UHFFFAOYSA-N 0.000 title claims description 10
- 239000003814 drug Substances 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 18
- 230000008569 process Effects 0.000 claims description 14
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 5
- 239000002244 precipitate Substances 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 5
- 239000011541 reaction mixture Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000002798 polar solvent Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000011877 solvent mixture Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- UYGNZRVLPYZLTF-UHFFFAOYSA-N 7-[4-[2-(4-fluorophenyl)ethyl]piperazine-1-carbonyl]-1h-indol-1-ium-3-carbonitrile;chloride Chemical compound Cl.C1=CC(F)=CC=C1CCN1CCN(C(=O)C=2C=3NC=C(C=3C=CC=2)C#N)CC1 UYGNZRVLPYZLTF-UHFFFAOYSA-N 0.000 abstract 1
- ZRXBCXGGXCXHCB-UHFFFAOYSA-N 7-[4-[2-(2,4-difluorophenyl)ethyl]piperazine-1-carbonyl]-1h-indole-3-carbonitrile Chemical compound FC1=CC(F)=CC=C1CCN1CCN(C(=O)C=2C=3NC=C(C=3C=CC=2)C#N)CC1 ZRXBCXGGXCXHCB-UHFFFAOYSA-N 0.000 description 32
- 239000000203 mixture Substances 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 10
- 239000012458 free base Substances 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 238000003825 pressing Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000000634 powder X-ray diffraction Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 238000003860 storage Methods 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 238000001069 Raman spectroscopy Methods 0.000 description 3
- 238000001237 Raman spectrum Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 101150104779 HTR2A gene Proteins 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000000418 atomic force spectrum Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960005168 croscarmellose Drugs 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- -1 for example Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960000443 hydrochloric acid Drugs 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004047517A DE102004047517A1 (de) | 2004-09-28 | 2004-09-28 | Neuartige Kristallform von (3-Cyan-1H-indol-7-yl)-[4-(4-fluorphenethyl)-piperazin-1-yl]-methanon, Hydrochlorid |
| DE102004047517.2 | 2004-09-28 | ||
| PCT/EP2005/009647 WO2006034774A1 (de) | 2004-09-28 | 2005-09-08 | Neuartige kristallform von (3-cyan-1h-indol-7-yl)-[4-(4-fluorphenethyl)-piperazin-1-yl]-methanon, hydrochlorid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2581834A1 true CA2581834A1 (en) | 2006-04-06 |
Family
ID=35285234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002581834A Abandoned CA2581834A1 (en) | 2004-09-28 | 2005-09-08 | Novel crystal form of (3-cyano-1h-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone, hydrochloride |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7981897B2 (enExample) |
| EP (1) | EP1794121B1 (enExample) |
| JP (1) | JP5160892B2 (enExample) |
| KR (1) | KR20070057872A (enExample) |
| CN (1) | CN101027284B (enExample) |
| AR (1) | AR051043A1 (enExample) |
| AU (1) | AU2005289169B2 (enExample) |
| BR (1) | BRPI0516200A (enExample) |
| CA (1) | CA2581834A1 (enExample) |
| DE (1) | DE102004047517A1 (enExample) |
| MX (1) | MX2007003471A (enExample) |
| PE (1) | PE20060964A1 (enExample) |
| RU (1) | RU2383532C2 (enExample) |
| TW (1) | TW200616952A (enExample) |
| WO (1) | WO2006034774A1 (enExample) |
| ZA (1) | ZA200703440B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2016052B1 (en) * | 2006-05-05 | 2012-06-06 | Merck Patent GmbH | Crystalline (3-cyano-1h-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone phosphate |
| CN101437793B (zh) * | 2006-05-05 | 2012-08-22 | 默克专利股份有限公司 | 结晶的（3-氰基-1h-吲哚-7-基）-[4-（4-氟苯乙基）哌嗪-1-基]甲酮磷酸盐 |
| CA2756796C (en) * | 2007-05-11 | 2018-05-22 | Forest Laboratories Holdings Limited | Novel solvate and crystalline forms of carbamoyl-cyclohexane derivatives |
| HUP0700353A2 (en) * | 2007-05-18 | 2008-12-29 | Richter Gedeon Nyrt | Metabolites of (thio)carbamoyl-cyclohexane derivatives |
| US7875610B2 (en) * | 2007-12-03 | 2011-01-25 | Richter Gedeon Nyrt. | Pyrimidinyl-piperazines useful as D3/D2 receptor ligands |
| EP2251011B1 (en) * | 2008-02-21 | 2012-04-04 | Richter Gedeon Nyrt. | Solid preparation for oral administration |
| SI2317852T1 (sl) | 2008-07-16 | 2015-04-30 | Richter Gedeon Nyrt. | Farmacevtske formulacije, ki vsebujejo ligande dopaminskega receptorja |
| HU230067B1 (hu) | 2008-12-17 | 2015-06-29 | Richter Gedeon Nyrt | Új piperazin só és eljárás előállítására |
| HUP0800765A2 (en) | 2008-12-18 | 2010-11-29 | Richter Gedeon Nyrt | A new process for the preparation of piperazine derivatives and their hydrochloric salts |
| HUP0800766A2 (en) | 2008-12-18 | 2010-11-29 | Richter Gedeon Vegyeszet | Process for the preparation of piperazine derivatives |
| US8912197B2 (en) | 2012-08-20 | 2014-12-16 | Forest Laboratories Holdings Ltd. | Crystalline form of carbamoyl-cyclohexane derivatives |
| US11274087B2 (en) | 2016-07-08 | 2022-03-15 | Richter Gedeon Nyrt. | Industrial process for the preparation of cariprazine |
| US11547707B2 (en) | 2019-04-10 | 2023-01-10 | Richter Gedeon Nyrt. | Carbamoyl cyclohexane derivatives for treating autism spectrum disorder |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2084531A1 (en) * | 1991-12-19 | 1993-06-20 | David W. Smith | Antimigraine 4-pyrimidinyl and pyridinyl derivatives of indol-3yl-alkyl piperazines |
| DE19934433A1 (de) * | 1999-07-22 | 2001-01-25 | Merck Patent Gmbh | N-(Indolcarbonyl-)piperazinderivate |
| DE10102944A1 (de) | 2001-01-23 | 2002-07-25 | Merck Patent Gmbh | Verfahren zur Herstellung von (3-Cyan-1H-indol-7-yl)-[4-(4-fluorphenethyl)-piperazin-1-yl]-methanon und dessen Salzen |
| DE10157673A1 (de) * | 2001-11-24 | 2003-06-05 | Merck Patent Gmbh | Verwendung von N-(Indolcarbonyl-)piperazinderivaten |
| DE10246357A1 (de) * | 2002-10-04 | 2004-04-15 | Merck Patent Gmbh | Verwendung von 5-HT2Rezeptorantagonisten |
-
2004
- 2004-09-28 DE DE102004047517A patent/DE102004047517A1/de not_active Withdrawn
-
2005
- 2005-09-08 WO PCT/EP2005/009647 patent/WO2006034774A1/de not_active Ceased
- 2005-09-08 CN CN2005800326518A patent/CN101027284B/zh not_active Expired - Fee Related
- 2005-09-08 BR BRPI0516200-9A patent/BRPI0516200A/pt not_active IP Right Cessation
- 2005-09-08 EP EP05782871.7A patent/EP1794121B1/de not_active Expired - Lifetime
- 2005-09-08 MX MX2007003471A patent/MX2007003471A/es not_active Application Discontinuation
- 2005-09-08 US US11/576,086 patent/US7981897B2/en not_active Expired - Fee Related
- 2005-09-08 CA CA002581834A patent/CA2581834A1/en not_active Abandoned
- 2005-09-08 RU RU2007116037/04A patent/RU2383532C2/ru not_active IP Right Cessation
- 2005-09-08 AU AU2005289169A patent/AU2005289169B2/en not_active Ceased
- 2005-09-08 KR KR1020077006952A patent/KR20070057872A/ko not_active Ceased
- 2005-09-08 JP JP2007532794A patent/JP5160892B2/ja not_active Expired - Fee Related
- 2005-09-23 TW TW094133161A patent/TW200616952A/zh unknown
- 2005-09-26 PE PE2005001111A patent/PE20060964A1/es not_active Application Discontinuation
- 2005-09-28 AR ARP050104084A patent/AR051043A1/es unknown
-
2007
- 2007-04-26 ZA ZA200703440A patent/ZA200703440B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20060964A1 (es) | 2006-10-02 |
| CN101027284B (zh) | 2010-09-29 |
| DE102004047517A1 (de) | 2006-03-30 |
| JP5160892B2 (ja) | 2013-03-13 |
| EP1794121A1 (de) | 2007-06-13 |
| AR051043A1 (es) | 2006-12-13 |
| US7981897B2 (en) | 2011-07-19 |
| CN101027284A (zh) | 2007-08-29 |
| WO2006034774A1 (de) | 2006-04-06 |
| BRPI0516200A (pt) | 2008-08-26 |
| EP1794121B1 (de) | 2013-12-25 |
| AU2005289169B2 (en) | 2011-07-14 |
| JP2008514558A (ja) | 2008-05-08 |
| AU2005289169A1 (en) | 2006-04-06 |
| ZA200703440B (en) | 2008-08-27 |
| TW200616952A (en) | 2006-06-01 |
| KR20070057872A (ko) | 2007-06-07 |
| RU2007116037A (ru) | 2008-11-10 |
| US20070259885A1 (en) | 2007-11-08 |
| MX2007003471A (es) | 2007-05-10 |
| RU2383532C2 (ru) | 2010-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5714824B2 (ja) | １−４−（５−シアノインドール−３−イル）ブチル−４−（２−カルバモイルベンゾフラン−５−イル）ピペラジン塩酸塩の多形相 | |
| CA2581834A1 (en) | Novel crystal form of (3-cyano-1h-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone, hydrochloride | |
| KR102442536B1 (ko) | 리나글립틴 결정형 및 이의 제조방법 | |
| JP2025511847A (ja) | ラニフィブラノールの結晶形態 | |
| KR20170078710A (ko) | Jak 키나아제 억제제 바이설페이트의 결정형 및 이의 제조방법 | |
| KR20170057441A (ko) | Jak 억제제의 바이설페이트의 결정형 및 이의 제조방법 | |
| MXPA02001369A (es) | Torasemidas polimorfas. | |
| WO2019003249A1 (en) | POLYMORPHIC FORMS OF BARICITINIB | |
| CA2614545A1 (en) | Choline salt crystal of azulene compound | |
| TWI499584B (zh) | ４－｛３－［順－六氫環戊［ｃ］吡咯－２（１ｈ）－基］丙氧基｝苯甲醯胺鹽酸鹽之晶形及其合成方法及含彼之醫藥組合物 | |
| CA2528192A1 (en) | Cristalline ziprasidone hcl and processes for preparation thereof | |
| CA2464961A1 (en) | Polymorphous forms of rosiglitazone maleate | |
| MX2007001827A (es) | Nuevas sustancias polimorfas de azabiciclohexano. | |
| KR101557832B1 (ko) | (ｒ)-3-플루오로페닐-3,4,5-트리플루오로벤질카르밤산 1-아자비시클로 [2.2.2]옥트-3-일 에스테르의 안정한 결정성 염 | |
| JP6761564B2 (ja) | ナトリウム・グルコース共輸送体２阻害薬のｌ−プロリン化合物、およびｌ−プロリン化合物の一水和物および結晶 | |
| KR102013567B1 (ko) | ６-(피페리딘-４-일옥시)-２ｈ-이소퀴놀린-１-온 하이드로클로라이드의 다형체 | |
| NO327100B1 (no) | Sitronsyre-salt, farmasoytisk preparat inneholdende slike samt anvendelse av disse for fremstilling av medikament til medisinsk behandling | |
| JP4171413B2 (ja) | フェニルエタノールアミンの結晶形およびそれを含む医薬組成物 | |
| HK1105413A (en) | Novel crystalline form of (3-cyano-1h-indol-7-yl)-[4-(4-fluorophenethyl)-piperazine-1-yl]-methanon hydrochloride | |
| KR100372964B1 (ko) | 피페리딘유도체결정,이의제조용중간생성물및이의제조방법 | |
| JP5450927B2 (ja) | 塩酸テモカプリルのｉ型結晶の製造方法 | |
| WO2013163917A1 (zh) | 化合物jk12a及其制备 | |
| EP1713769B1 (en) | Amorphous tamsulosin hydrochloride | |
| AU2023253008A1 (en) | Polymorph of 7,8-dihydroxyflavone, and preparation method therefor | |
| WO2001019368A1 (fr) | Preparations a base de derives de quinolinone et procede de fabrication |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20150305 |